SWT 01100

Drug Profile

SWT 01100

Alternative Names: SWT 01.100

Latest Information Update: 02 Jun 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SWITCH Biotech (CEASED)
  • Class Antipsoriatics
  • Mechanism of Action Ion channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Psoriasis

Most Recent Events

  • 01 Mar 2005 Discontinued - Phase-II for Psoriasis in Germany (Topical)
  • 01 Mar 2005 SWITCH Biotech has closed down
  • 22 Mar 2004 Phase-II clinical trials in Psoriasis in Germany (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top